Results 181 to 190 of about 6,178 (191)

Adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets

Current Medical Research and Opinion, 2018
Mei Sheng Duh, Francis Vekeman, Priyanka Bobbili   +2 more
exaly  

Deferasirox at therapeutic doses is associated with dose-dependent hypercalciuria

Bone, 2016
James C G Doery, Ian Larmour
exaly  

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study

Annals of Hematology, 2013
Ali Taher, Noppadol Siritanaratkul, Suporn Chuncharunee   +2 more
exaly  

Deferasirox

Drugs of the Future, 2004
null McIntyre, J.A., null Castaner, J., null Mealy, N.E., null Bayes, M.   +3 more
openaire   +1 more source

A simple LC–MS/MS method for determination of deferasirox in human plasma: Troubleshooting of interference from ferric ion in method development and its application

Journal of Pharmaceutical and Biomedical Analysis, 2018
Li Ding, Wen Yang, Zhiming Cui
exaly  

Ag Nanoparticles-enhanced Fluorescence of Terbium-Deferasirox Complexes for the Highly Sensitive Determination of Deferasirox

Analytical Sciences, 2016
Javad Hassanzadeh, Jafar Abolhasani
exaly  

Absolute Oral Bioavailability and Disposition of Deferasirox in Healthy Human Subjects

Journal of Clinical Pharmacology, 2008
exaly  

Summary of opinion: Deferasirox Mylan,deferasirox

Case Medical Research, 2019
openaire   +1 more source

Synthesis and Characterization of Related Substances of Deferasirox, an Iron (Fe3+) Chelating Agent

Synthetic Communications, 2012
exaly  

Hyperchloraemic metabolic acidosis induced by the iron chelator deferasirox: a case report and review of the literature

Journal of Clinical Pharmacy and Therapeutics, 2013
exaly